Knights Of Columbus Asset Advisors LLC Genmab A/S Transaction History

Knights Of Columbus Asset Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$27.94 - $35.44 $28,498 - $36,148	1,020 Added 17.86%	6,732 $214,000
Q3 2023 Nov 01, 2023	BUY	$35.27 - $42.24 $28,991 - $34,721	822 Added 16.81%	5,712 $201,000
Q2 2023 Jul 31, 2023	BUY	$37.4 - $42.94 $51,799 - $59,471	1,385 Added 39.51%	4,890 $185,000
Q1 2023 May 01, 2023	BUY	$34.88 - $43.22 $2,755 - $3,414	79 Added 2.31%	3,505 $132,000
Q4 2022 Jan 31, 2023	BUY	$33.8 - $47.06 $115,798 - $161,227	3,426 New	3,426 $145,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.